NEW YORK, March 23, 2017 /PRNewswire/ -- China currently has the highest number of diabetics in the world. The disease has presently reached epidemic proportions in the adult population. Around three decades ago, less than one percent of the Chinese adult population had diabetes. These levels, however, have increased to around 12 percent - making it the diabetes capital of the world. The rise of diabetes in China can be attributed to a number of factors. Driven by a strong economic growth over the past few decades, the Chinese population has become richer, fatter and less mobile. Apart from urbanisation and sedentary lifestyles, Chinese people are also genetically more vulnerable to diabetes compared to Europeans and many other population groups. Other factors such as poor awareness of health issues, high consumption of white rice, poor healthcare infrastructure, etc. have also driven the prevalence of the disease. China's diabetes statistics may ring alarm bells for the government and healthcare authorities, for drug and diagnostic manufacturers, however, it represents a goldmine. Fuelled by a continuous increase in healthcare expenditures, the market for diabetes drugs and diagnostics is expanding robustly in the country. This is creating lucrative opportunities for global healthcare companies at a time when growth rates in the more developed markets have declined. IMARC's new report "China Diabetes Market Report: Patients, Prevalence, Oral Antidiabetics, Insulin and Diagnostics" provides an analytical and statistical insight into the Chinese diabetes market. The report provides both current and future trends in the prevalence, demographical breakup, diagnosis and treatment of diabetes in China. The research study serves as an exceptional tool to understand the epidemiology, market trends, therapeutic structure, competitive structure and the outlook of the Chinese diabetes market. This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who are planning to foray into the China diabetes market in any form. What we have achieved in this report?
Comprehensive situation analysis of the Chinese diabetes epidemiology and its dynamics:
Focus of the Analysis: Historical, current and future prevalence of diabetes in China
Historical, current and future prevalence of type-1 and type-2 diabetes in China
Historical, current and future prevalence of diabetes in the urban and rural regions in China
Historical, current and future prevalence of diabetes among males and females in China
Historical, current and future prevalence of diabetes among various age groups in China
Historical, current and future diagnosis rates for diabetes in China
Historical, current and future drug treatment rates for diabetes in China
Comprehensive situation analysis of the Chinese Oral Antidiabetics market and its dynamics:
Focus of the Analysis: Performance of the Oral Antidiabetics market in China
Performance of key classes Performance of key players Market outlook Comprehensive situation analysis of the Chinese Insulin market and its dynamics:
Focus of the Analysis: Performance of the Insulin market in China
Performance of key classes Performance of key players Market outlook Comprehensive situation analysis of the Chinese diabetes diagnostics market and its dynamics:
Focus of the Analysis: Performance of the diabetes diagnostics market in China
Market Segmentation Key players Market outlook Read the full report: http://www.reportlinker.com/p03451748-summary/view-report.htmlAbout Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.http://www.reportlinker.com__________________________Contact Clare: [email protected]US: (339)-368-6001Intl: +1 339-368-6001
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/china-diabetes-market-report-patients-prevalence-oral-antidiabetics-insulin-and-diagnostics-300428709.html
SOURCE Reportlinker
